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INTRODUCTION
Despite the wide use of the novel agents bortezomib, 
thalidomide and lenalidomide, and the administration 
of high dose therapy (HDT) with autologous stem 
cell transplantation (ASCT), multiple myeloma (MM) 
remains incurable, with relapses occurring even in 
patients achieving prolonged and high quality duration 
of response with initial therapy, owing to development 
of drug resistance. To overcome this drug resistance, 
numerous therapeutic approaches have been developed, 
and include new-generation proteasome inhibitors such 
as carfilzomib and ixazomib, next-generation immuno-
modulatory drugs such as pomalidomide, and mono-
clonal antibodies. Management of relapsed MM remains 
challenging and requires a careful evaluation.
DEFINITION
Relapsed MM refers to a recurrence or a progression of 
the disease, defined as at least a 25% increase from 
baseline of the serum monoclonal protein (M-protein)
(absolute increase ≥ 500 mg/dl), urine M-protein (abso-
lute increase > 200mg/day), ≥ 25% difference between 
involved and uninvolved serum free light chain (FLC) 
level (absolute increase > 10mg/dl), or appearance of new 
bone lesions or plasmacytomas, or hypercalcemia, that 
cannot be attributed to other causes. In non-secretory 
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MM, relapse is defined as an increase in the percentage 
plasma cells in bone marrow (absolute increase > 10%). 
Relapsed and refractory multiple myeloma (RRMM) 
refers to a progression occurring on salvage therapy or 
within 60 days after completion of the last treatment in 
patients who previously achieved at least a minimal 
response (MR) (Table 1).1 
DIAGNOSTIC WORK-UP
Evaluation at relapse should include medical history 
and physical examination, complete blood count, serum 
creatinine, calcium and lactate dehydrogenase (LDH) 
determination, serum and urine (24-h collection) protein 
electrophoresis and immunofixation, serum FLC assay 
and a bone marrow (BM) aspirate with fluorescence in 
situ hybridisation (FISH) analysis performed on CD138 
selected plasma cells (PC) to identify new chromosomal 
abnormalities. Imaging with skeletal survey (x-rays or 
low-dose CT), magnetic resonance imaging or in selected 
cases, FDG-positron emission tomography allows for 
assessment of new sites of disease, evaluation of pre- 
existing involved lesions or extramedullary (EM) disease. 
International staging system (ISS) stage determination 
is not mandatory since its role at relapse is unclear.2 
INDICATION FOR TREATMENT: OPTIMAL 
TIMING TO INITIATE THERAPY AT 
RELAPSE
The goal of treatment at relapse is to relieve symptoms 
or prevent the appearance of CRAB features. 
Treatment is mandatory in patients with a symptomatic 
relapse, but should also be considered in case of rapidly 
increasing M-protein concentration (doubling time of 
≤ 3 months) or light chain (LC) escape even without 
associated symptoms, as well as in high-risk MM, 
characterised by adverse cytogenetics or previous renal 
failure related to LC at diagnosis.3,4
In asymptomatic biochemical relapse or in case of 
slow rise in the M-protein level, strict follow-up at least 
every three months is recommended until significant 
progression.5 
DETERMINANTS OF THERAPY
Several factors should be taken into account while deter-
mining the treatment strategy in the setting of relapse. 
They are based on both patient- and disease-related 
factors, including pre-existing toxicities, co-morbidities, 
prior response to therapy, aggressiveness of relapse and 
cytogenetics (Table 2).6,7 
Performance status, frailty, patient’s preferences and 
expectations should also be taken into account, parti-
cularly in the elderly, since toxicity is a major problem 
that can result in early treatment discontinuation and 
poorer outcome.8 Salvage regimen should therefore offer 
an adequate balance between efficacy and toxicity, with 
quality of life as a major goal. 
Risk should be determined based on prior cytogenetic 
abnormalities, but also on aggressive clinical features 
such as extensive bone disease, EM disease or organ 
dysfunction such as renal failure.9,10 Time to relapse 
should also be considered in determination of risk, since 
short duration of response (DOR) to prior treatment or 
progression under current therapy are associated with 
poorer outcome (Table 3).9,11 
TABLE 1. Definitions of relapsed and refractory multiple myeloma (adapted from Rajkumar, Blood 2001). 
Primary refractory MM Non responsive disease, in whom MR or better has never been achieved, with no 
significant change in M-protein level and no evidence of clinical progression
Refractory MM Non responsive disease, while on primary or salvage therapy, or progressing withoin 
60 days of last therapy 
Relapsed MM Previously responding disease, that progresses and requires initiation of salvage 
therapy, but does not meet criteria forveither primary refractory disease or relapsed 
and refractory disease
Relapsed and refractory MM Non responsive disease, while on salvage therapy or progressing within 60 days of last 
therapy, in patients who have achieved at least MR at some point previously before, 
then progressing in their course
Double refractory MM Disease refractory to both PI and IMiDs
Abbreviations: IMiDs, immunomodulatory drugs; MR, minimal response; PI, proteasome inhibitors. 
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KEY PRINCIPLES: GENERAL 
CONSIDERATIONS
MM is characterised by relapses and remissions, the 
remission duration in RRMM decreasing with each 
regimen.12 This is in relation to a more aggressive 
tumour behaviour at each relapse due to the selection 
of resistant clones responsible for progressive disease 
refractoriness.13 In patients refractory to lenalidomide 
and bortezomib, median progression-free survival (PFS) 
and overall survival (OS) do not exceed five and nine 
months, respectively.14
Front line regimens can be considered in the relapsed 
setting. Patients should, however, always be considered 
for enrolment on to clinical trials.
Eligibility for HDT should also be considered, as ASCT 
remains a reasonable option in eligible patients who 
have not previously undergone ASCT and in those 
who experienced a remission duration of at least 18-24 
months without maintenance therapy after the first 
procedure.15,16
Patients naïve to an agent or a class of drugs are preferably 
treated with a regimen incorporating this agent. Re- 
administration of an agent initially proven to be effective 
can be proposed, provided it induced at least a partial 
response (PR) with a DOR of at least six to nine months, 
or a response duration that averaged or exceeded the 
median duration based on clinical trial results with 
that agent or regimen used in a similar setting. If an 
effective alternative therapy is available, switching drug 
class is preferred.17
Usually, doublet or triplet regimens are preferred above 
single agents in order to achieve a maximal response, 
but selected frail patients or indolent relapses can often 
be treated with less intense regimens.18 
Duration of therapy should be determined by the drug 
label and by the clinical context of the patient. In the 
absence of toxicity, most regimens are continued until 
progression, but stopping therapy may be reasonable 
once a stable plateau has been reached, especially 
when using thalidomide, bortezomib, carfilzomib or 
alkylators, in order to minimise risk of serious toxicity.
CURRENT TREATMENT OPTIONS
Major regimens used in relapse are listed in Tables 4 & 5.
IMMUNOMODULATORY DRUGS (IMiDs)
Immunomodulatory drugs are effective in MM through 
several mechanisms including the recently discovered 
binding to cereblon, a critical component of the E3 
ubiquitin ligase complex, responsible for the degradation 
of two important factors for myeloma cell survival, 
Aiolos (IKZF3) and Ikaros (IKZF1), leading to myeloma 
cell death.19
Thalidomide has long been considered a valuable treat-
ment option in RRMM. Its current role is restricted by 
the lack of randomised phase III data supporting its 
use as single agent, the use of next-generation IMiDs, 
the absence of data on its efficacy in lenalidomide- and 
pomalidomide-refractory patients and the important 
side-effects observed with prolonged use.
As a single agent, it provides an overall response rate 
(ORR)(PR or better) of 30% with a median OS of 
fourteen months.20 Efficacy is further improved in com-
bination with dexamethasone (ORR of 41-56%, PFS of 
TABLE 2. Factors influencing choice of therapy. 
Disease-related factors Treatment-related factors Patient-related factors
risk stratification prior drug therapy renal and hepatic impairment
acquired chromosomal aberrations regimen-related toxicities co-morbidities
presence of end-organ damage polyneuropathy, myelosuppression susceptibility to infections
presence of extramedullary disease depth and duration of response to prior drug performance status
frailty




seventeen months, 3-year survival probability of 60%) 
or with other drugs such as bortezomib, cyclophos- 
phamide, or pegylated liposomal doxorubicin, in triplet 
or quadruplet combinations (ORR of 63-90%, complete 
response (CR) in 2-35%)(Table 4).21-28
Lenalidomide is more potent and less toxic than thalido-
mide, and is active as a single agent with PR rates of 
24-29%.29 Addition of dexamethasone improves res-
ponse rates by up to 30%.30 Analysis of the pooled data 
from the MM-009 and MM-010 trials after a follow-up 
of 48 months reported a significantly improved ORR 
(60.6% versus 21.9%), DOR (15.8 months versus 7 
months), median time-to-progression (TTP)(13.4 months 
versus 4.6 months) and OS (38 months versus 31.6 
months).31 To achieve a maximum PFS, treatment 
requires at least twelve months full-dose lenalidomide 
plus dexamethasone, followed by lower-dose continued 
therapy.32 In patients with suboptimal response, addi-
tion of cyclophosphamide can provide a clinical 
benefit.33 In patients achieving at least PR, continued 
lenalidomide therapy until disease progression is asso-
ciated with a survival advantage.34 The combination of 
lenalidomide, bortezomib and dexamethasone (RVD) 
is a very active and well-tolerated regimen that can 
overcome drug resistance in patients previously treated 
with lenalidomide, bortezomib, thalidomide or ASCT. 
With a follow-up >2 years, CR/nCR are reported in 
25% of patients, ≥PR in 64% of them, with a median 
PFS of 9.5 months and a median OS of 26 months 
(Table 4).35
Pomalidomide is a third generation IMiD, with sig- 
nificant activity in RRMM, even in patients failing 
lenalidomide and lenalidomide plus bortezomib.36-39 It 
has been approved for the treatment of patients who 
received at least three prior lines of therapies including 
lenalidomide and bortezomib. In patients refractory to 
both bortezomib and lenalidomide, response rate is 
approximately 30% with a DOR of 7-8 months.39,40 
Compared to high-dose dexamethasone alone, poma-
lidomide with weekly dexamethasone provides a sig- 
nificantly longer PFS (4 months versus 1.9 months) and 
OS (12.7 months versus 8.1 months).41 Pomalidomide 
is also the first drug to have shown increased activity in 
patients with del(17p).42 It can be safely combined with 
other drugs such as bortezomib, carfilzomib, cyclo- 
phosphamide or clarithromycin, resulting in deeper 
responses in RRMM patients (Tables 4 & 5).43-46 
PROTEASOME INHIBITORS (PIs)
PIs alter the ability of the proteasome to degrade intra- 
cellular proteins that have been targeted for destruction, 
leading to protein accumulation and eventually plasma 
cell apoptosis.47
Bortezomib is the first-in-class PI developed for the 
treatment of MM. As single agent, compared with high- 
dose dexamethasone in the APEX trial, bortezomib is 
associated with higher ORR (38% versus 18%), TTP 
(6.2 months versus 3.5 months), and 1-year OS (80% 
versus 66%).48 All-grade polyneuropathies (PN) occur 
in one-third of patients, a side effect that can be reduced 
PRACTICE GUIDELINES
TABLE 3. High-risk disease characteristics in RRMM (adapted from Laubach, Leukemia 2016).
Adverse cytogenetic abnormalities (hypodiploidy, t(4;14), del (17p), amp(1q21))
ISS stage II or III 
Extramedullary disease
Short duration of response to prior therapy or progression while on current therapy
Aggressive clinical features including
• Rapid onset of clinical symptoms
• Extensive disease at relapse based on laboratory, pathology, or radiographic findings




TABLE 4. Selected regimens used in RRMM.
Drug Regimens N dose phase prior lines ≥PR (≥VGPR), % PFS, months OS, months ≥grade 3 AE, % references
Thalidomide TD 44 T 200mg orally 2 3 55 (NA) 4.2 12 C 75, S 57, PN 23 21
D 20mg/m2 d1-4,d9-12,d17-20 (cycle 1), d1-4 (cycles 2+)
CTD 53 C 150mg/m2 q12h orally d1-5 2 NA 75 (36) 12 17.5 TEE 4, PN 2 24
T 400mg orally d1-5,d14-18
D 20mg/m2 d1-5,d14-18
PLD-TD 47 T 100mg matched cases 3 75 (36) 21 35.5 N 25, PN 2, T 7,  I 23, TEE 13 26
PLD 40mg/m2 d1
D 40mg orally d1-4,d9-12, 28d-cycles
Lenalidomide RD 176 R 25mg orally d1-21 3 ≥2 60(24CR) NA NR N 30, A 8, T12, P2, F 6 89
D 40mg orally d1-4,d9-12,d17-20, 28d-cycles
REP 14 R 10mg orally d1-21 - 2 50 (35) 12.8 93 at 1y A , N, T, P 33
E (C) orally 100mg  d1-28
P orally 20/10mg d1-28, 28d-cycles
RVD 64 R 15mg orally d1-14 2 2 64(28) 9.6 30 N 30, T 22, L 11 40
V 1mg/m2 IV d1,d4,d8,d11
D 40/20mg 
Pomalidomide PD 302 P 4mg orally d1-21 3 5 31(6) 4 12.7 N 48, A 33, T 22, F 5, I 34 41
D 40mg orally d1,d8,d15,d22
PCD 80 P 4mg orally d1-21 2 4 64.7 9.5 NR N 52, A 24, T15 45
C 300-500mg d1,d8,d15
D 40mg orally d1,d8,d15,d22, 28d-cycles
PKD 32 P 4mg orally d1-21 1 6 50(16) 7.2 at 26 
months
F 43, N 40, A34, T 34, D 20 44
K 20/27mg/m2 IV d1,d2,d8,d9,d15,d16
D 40mg orally d1,d8,d15,d22, 28d-cycles
Bortezomib VD 315 V 1mg/m2 IV d1,d4,d8,d11 3 2 38(6CR) TTP 6.22 80% at 1y D 7, F 5, PN 8, A 10, T 30, N 14 48
D 40mg d1,d8,d15,d22, 28d-cycles
V-PLD 324 V 1mg/m2 IV d1,d4,d8,d11 3 ≥2 44(27) 9 33 N 29, A 9, T 23, PN 3 54, 69
PLD 30mg/m2 IV d4
VTD 135 V 1-1.3mg/m2 d1,d4,d8,d11 3 NA 87(56) 18.3 71% at 2y N 11, A 8, T 17, PN 31, I 14 23
T 200mg orally 
D 40mg orally d1,d8,d15,d22
VCD 96 V 1-1.3mg/m2 d1,d8,d15 - 1 to 3 69(43) 16.2 26.3 A 6, T 9, N 6, PN 4, P 6 51
C 300mg/m2 orally d1,d8,d15,d22,
D 40mg orally d1,d8,d15,d22, 28d-cycles
Pan-VD 387 Pan 20mg d1, d3, d5, d8, d10, d12, 21d-cycles 3 1 to 3 61 12 33.7 T 67, D 53, D 26 73
V 1.3mg/m2 d1,d4,d8,d11
D 20mg orallyd1, d2, d4, d5, d8, d9, d11, d12
VDB 75 V 1.3mg/m2 IV d1,d4,d8,d11 2 4 71.5(34.5) 16.5 78% N 18, T 30, I 12, PN 8 55
D 20mg orally d1, d2, d4, d5, d8, d9, d11, d12
B 70mg/m2 IV d1,d8, 28d-cycles
Carfilzomib Kd 464 K 20/56mg/m2 IV d1,d2,d8,d9,d15,d16 3 1 to 3 76(54) 18.7 NA A 14, H 9, T 8, P 7 60
D 20mg d1,d2,d8,d9,d15,d16,d22,d23
KRD 396 K 20/27mg/m2 IV d1,d2,d8,d9,d15,d16 3 2 87(70) 26.3 NR D 4, F 8 19
R 25mg orally d1-21
D 40mg orally d1,d8,d15,d22, 28d-cycles
Elotuzumab Elo-RD 321 Elo 10mg/kg weekly cycles 1-2, every other week cycles 3+ 3 1 to 3 79(4) 19.4 NA L 77, N 34, A 19, T 19, F 8 75
R 25mg d1-d21
d 40mg d1,d8,d15,d22, 28d-cycles
Elo-VD 77 Elo 10mg/kg weekly cycles 1-2, every other week cycles 3+ 2 1 to 3 66(36) 9.7 85% at 1y, 
73% at 2y
I 21, D 8, A 7, PN 9 76
V 1.3mg/m2 d1,d4,d8,d11
d 20mg d1,d8,d15,d22, 28d-cycles
Daratumumab Dara 72 Dara 8-16mg/kg 1x/w (2m), 1x/2w (4m), 1x/m (18m) 1/2 4 36 5.6 NA P , T 78
Dara-VD 240 Dara 16mg/kg IV d1, d8, d15 (cycles 1-3), d1 (cycles 4+) 3 ≥1 83(59) 60.7% at 1y NA T 45, A 14, N 13 80
V 1mg/m2 IV d1,d4,d8,d11
D 20mg d1, d2, d4, d5, d8, d9, d11, d12
Dara-RD 286 Dara 16mg/kg IV d1, d8, d15 (cycles 1-2), d1 (cycles 3+) 3 ≥1 93(76) 83% at 1y, 
76% at 18m
NA N 52, T 13, A 12 81
R 25mg d1-d21
D 40mg/week, 28d-cycles, until progression
Abbreviations: B, bendamustine; C, cyclophosphamide; Cla, clarithromycin; D, dexamethasone; Dara, daratumumab; 
E, cyclophosphamide; Elo, elotuzumab; K, carfilzomib; P, prednisone; Pan, panobinostat; PLD, pegylated liposomal doxorubicin; 
P, pomalidomide; R, lenalidomide; T, thalidomide; V, bortezomib 
AE, adverse events; C, constipation; CR, complete response; D, diarrhea; F, fever; I, infections; L, lymphopenia; 
NA, not available; NR, not reached; PN, polyneuropathy; S, somnolence; T, thrombocytopenia; TTP, time-to-progression; 
TEE, thromboembolic events; y, years
58PRACTICE GUIDELINES
TABLE 4. Selected regimens used in RRMM.
Drug Regimens N dose phase prior lines ≥PR (≥VGPR), % PFS, months OS, months ≥grade 3 AE, % references
Thalidomide TD 44 T 200mg orally 2 3 55 (NA) 4.2 12 C 75, S 57, PN 23 21
D 20mg/m2 d1-4,d9-12,d17-20 (cycle 1), d1-4 (cycles 2+)
CTD 53 C 150mg/m2 q12h orally d1-5 2 NA 75 (36) 12 17.5 TEE 4, PN 2 24
T 400mg orally d1-5,d14-18
D 20mg/m2 d1-5,d14-18
PLD-TD 47 T 100mg matched cases 3 75 (36) 21 35.5 N 25, PN 2, T 7,  I 23, TEE 13 26
PLD 40mg/m2 d1
D 40mg orally d1-4,d9-12, 28d-cycles
Lenalidomide RD 176 R 25mg orally d1-21 3 ≥2 60(24CR) NA NR N 30, A 8, T12, P2, F 6 89
D 40mg orally d1-4,d9-12,d17-20, 28d-cycles
REP 14 R 10mg orally d1-21 - 2 50 (35) 12.8 93 at 1y A , N, T, P 33
E (C) orally 100mg  d1-28
P orally 20/10mg d1-28, 28d-cycles
RVD 64 R 15mg orally d1-14 2 2 64(28) 9.6 30 N 30, T 22, L 11 40
V 1mg/m2 IV d1,d4,d8,d11
D 40/20mg 
Pomalidomide PD 302 P 4mg orally d1-21 3 5 31(6) 4 12.7 N 48, A 33, T 22, F 5, I 34 41
D 40mg orally d1,d8,d15,d22
PCD 80 P 4mg orally d1-21 2 4 64.7 9.5 NR N 52, A 24, T15 45
C 300-500mg d1,d8,d15
D 40mg orally d1,d8,d15,d22, 28d-cycles
PKD 32 P 4mg orally d1-21 1 6 50(16) 7.2 at 26 
months
F 43, N 40, A34, T 34, D 20 44
K 20/27mg/m2 IV d1,d2,d8,d9,d15,d16
D 40mg orally d1,d8,d15,d22, 28d-cycles
Bortezomib VD 315 V 1mg/m2 IV d1,d4,d8,d11 3 2 38(6CR) TTP 6.22 80% at 1y D 7, F 5, PN 8, A 10, T 30, N 14 48
D 40mg d1,d8,d15,d22, 28d-cycles
V-PLD 324 V 1mg/m2 IV d1,d4,d8,d11 3 ≥2 44(27) 9 33 N 29, A 9, T 23, PN 3 54, 69
PLD 30mg/m2 IV d4
VTD 135 V 1-1.3mg/m2 d1,d4,d8,d11 3 NA 87(56) 18.3 71% at 2y N 11, A 8, T 17, PN 31, I 14 23
T 200mg orally 
D 40mg orally d1,d8,d15,d22
VCD 96 V 1-1.3mg/m2 d1,d8,d15 - 1 to 3 69(43) 16.2 26.3 A 6, T 9, N 6, PN 4, P 6 51
C 300mg/m2 orally d1,d8,d15,d22,
D 40mg orally d1,d8,d15,d22, 28d-cycles
Pan-VD 387 Pan 20mg d1, d3, d5, d8, d10, d12, 21d-cycles 3 1 to 3 61 12 33.7 T 67, D 53, D 26 73
V 1.3mg/m2 d1,d4,d8,d11
D 20mg orallyd1, d2, d4, d5, d8, d9, d11, d12
VDB 75 V 1.3mg/m2 IV d1,d4,d8,d11 2 4 71.5(34.5) 16.5 78% N 18, T 30, I 12, PN 8 55
D 20mg orally d1, d2, d4, d5, d8, d9, d11, d12
B 70mg/m2 IV d1,d8, 28d-cycles
Carfilzomib Kd 464 K 20/56mg/m2 IV d1,d2,d8,d9,d15,d16 3 1 to 3 76(54) 18.7 NA A 14, H 9, T 8, P 7 60
D 20mg d1,d2,d8,d9,d15,d16,d22,d23
KRD 396 K 20/27mg/m2 IV d1,d2,d8,d9,d15,d16 3 2 87(70) 26.3 NR D 4, F 8 19
R 25mg orally d1-21
D 40mg orally d1,d8,d15,d22, 28d-cycles
Elotuzumab Elo-RD 321 Elo 10mg/kg weekly cycles 1-2, every other week cycles 3+ 3 1 to 3 79(4) 19.4 NA L 77, N 34, A 19, T 19, F 8 75
R 25mg d1-d21
d 40mg d1,d8,d15,d22, 28d-cycles
Elo-VD 77 Elo 10mg/kg weekly cycles 1-2, every other week cycles 3+ 2 1 to 3 66(36) 9.7 85% at 1y, 
73% at 2y
I 21, D 8, A 7, PN 9 76
V 1.3mg/m2 d1,d4,d8,d11
d 20mg d1,d8,d15,d22, 28d-cycles
Daratumumab Dara 72 Dara 8-16mg/kg 1x/w (2m), 1x/2w (4m), 1x/m (18m) 1/2 4 36 5.6 NA P , T 78
Dara-VD 240 Dara 16mg/kg IV d1, d8, d15 (cycles 1-3), d1 (cycles 4+) 3 ≥1 83(59) 60.7% at 1y NA T 45, A 14, N 13 80
V 1mg/m2 IV d1,d4,d8,d11
D 20mg d1, d2, d4, d5, d8, d9, d11, d12
Dara-RD 286 Dara 16mg/kg IV d1, d8, d15 (cycles 1-2), d1 (cycles 3+) 3 ≥1 93(76) 83% at 1y, 
76% at 18m
NA N 52, T 13, A 12 81
R 25mg d1-d21
D 40mg/week, 28d-cycles, until progression
Abbreviations: B, bendamustine; C, cyclophosphamide; Cla, clarithromycin; D, dexamethasone; Dara, daratumumab; 
E, cyclophosphamide; Elo, elotuzumab; K, carfilzomib; P, prednisone; Pan, panobinostat; PLD, pegylated liposomal doxorubicin; 
P, pomalidomide; R, lenalidomide; T, thalidomide; V, bortezomib 
AE, adverse events; C, constipation; CR, complete response; D, diarrhea; F, fever; I, infections; L, lymphopenia; 
NA, not available; NR, not reached; PN, polyneuropathy; S, somnolence; T, thrombocytopenia; TTP, time-to-progression; 
TEE, thromboembolic events; y, years
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by using subcutaneous (SC) administration.48,49 Borte-
zomib can be safely administered to patients with renal 
failure.50 Retreatment with bortezomib is effective if 
previous response lasted more than six months.17 Triplet 
regimens using bortezomib as backbone in combinations 
with lenalidomide, cyclophosphamide, thalidomide, 
anthracyclines, as well as bendamustine have reported 
high response rates in the relapsed setting, and are 
well tolerated when low-dose dexamethasone and 
weekly subcutaneous bortezomib schedules are used 
(Table 4).23,35,51-56
Carfilzomib is a second generation PI, epoxyketone 
tetrapeptide analog with irreversible binding to the pro-
teasome complex, approved for the treatment of RRMM 
TABLE 5. Selected recent clinical trials in RRMM.










PD 302 31 (1) 4 <0.0001 12.7 median, m N 48, A 33, T 19 41
D 153 10 (0) 1.9 8 median, m N 16, A 37, T 26
ASPIRE
Phase 3
KRd 396 87 (14) 26.3 0.0001 NR (2y OS 73.3%) 0.04 D 4, F 8 19
Rd 396 67 (13) 17.6 NR (2y OS 65%) D 4, F 6
ENDEAVOR
Phase 3
Kd 464 77 (13) 18.7 <0.0001 2y OS 65% 0.06 A 14, H 9, T 8, P 7 60
Vd 465 63 (6) 9.4 2y OS 72% A10, H 3, T 9, P 8
PANORAMA 1
Phase 3
Pan-Vd 387 61 (6) 12 <0.0001 33.7 median, m 0.26 T 67, L 53, D 26 73
Vd 381 55 (11) 8.1 30.4 median, m T 31, L 40, D 8
ELOQUENT 2
Phase 3
Elo-Rd 321 79 (4) 19.4 <0.001 NA L 77, N 34, A 19, 
T 19, F 8
75
Rd 325 66 (7) 14.9 L 49, N 44, A 21, 
T 20, F 8
TOURMALINE
Phase 3
IRd 360 78 (12) 20.6 0.012 NA N 23, T 19, D 6 64
Rd 362 72 (7) 14.7 N 24, T 9, D 6
CASTOR
Phase 3
Dara-VD 251 83(19) 60.7% at 1y NA T 45, A 14, N 13, 
PN 4, D 4
80
VD 247 63(9) 26.9% at 1y T 33, A 16, N 4, 
PN 7, D 1
POLLUX
Phase 3
Dara-RD 286 93(43) 83% at 1y, 
78% at 18m
<0.001 NA N 52, T 13, A 12 81
RD 283 76(19) 60% at 1y, 
52% at 18m
N 37, T 13, A 20
Abbreviations: D, dexamethasone; Dara, daratumumab; Elo, elotuzumab; I, ixazomib; K, carfilzomib; Pan, panobinostat; 
P, pomalidomide; R, lenalidomide; T, thalidomide; V, bortezomib; A, anemia; AE, adverse events; CR, complete response; D, diarrhea; 
F, fatigue; HT, hypertension; L, lymphopenia; m, months; n, number; N, neutropenia; NA, not available; OS, overall survival; PFS,  
progression-free survival; PN, polyneuropathy; PR, partial response; T, thrombocytopenia; TTP, time-to-progression; y, years
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in patients who have received at least two prior lines of 
therapy including bortezomib and an IMiD. In patients 
refractory or intolerant to both bortezomib and lena-
lidomide (PX-171-003 trial), single-agent carfilzomib 
exhibits an ORR of 24% with a median DOR of 7.8 
months, while in bortezomib-naïve patients (PX-171-
004 trial), ORR is approximately 50%.57,58 The ORR 
and PFS are also significantly longer for patients with 
standard cytogenetics compared to those with any 
cytogenetic abnormalities, with the exception of the 
translocation t(4;14) who fared as well as the patients 
with normal cytogenetic status.59
PRACTICE GUIDELINES
TABLE 6. Renal and hepatic dose adjustments.
Renal Liver
thalidomide no dose adjustment no dose adjustment
lenalidomide CrCl >50ml/min : no dose adjustment grade 3/4 toxicities judged to be related to lenalidomide, 
hold treatment and restart at the physician’s discretion  
at next lower dose level when toxicity has resolved to 
≤ grade 2
CrCl 30-50ml/min : 10mg qd
CrCl <30ml/min, non dialysis dependent : 15mg every 
other day
CrCl <30ml/min, dialysis dependent : 5mg qd, 
on dialysis days, following dialysis
pomalidomide avoid in patients with a serum creatinine >3.0mg/dl not recommended in serum bilirubin >2mg/dl and 
AST/ALT >3N
stop treatment in case of elevated liver enzymes during 
therapy; consider a lower dose after enzymes return to 
baseline values                               
bortezomib no dose adjustment bilirubine >1.5N, starting dose at 0.7mg/m2 in the first 
cycle, dose escalation to 1 mg/m2 or reduction to 0.5 mg/m2 
in subsequent cycles based on patient tolerability
carfilzomib if renal toxicity develops during treatment (serum 
creatinine x2N, or CrCl <15ml/min, or CrCL decrease 
to 50% of baseline, or need for dialysis), withhold dose; 
if attributable to the drug, resume when renal function 
has recovered to within 25% of baseline; start at 1 dose 
level reduction
liver enzymes should be monitored regularly and the dose 
should be reduced or withheld as appropriate (frequent 
increase of serum transaminases, rare cases of hepatic 
failure)
if not attributable to the drug, dosing resumed at 
physician’s discretion
patients under dialysis, administer the drug after dialysis
panobinostat no dose adjustment (no information in end stage renal 
failure)
bilirubine ≤1xN and AST >1.5-2xN, reduce dose to 15mg
bilirubine >1.5-2xN, any AST >1.5-2xN, reduce dose to 10mg
avoid in severe liver impairment
elotuzumab no dose adjustment no dose adjustment for mild/moderate liver impairment 
before therapy 
grade ≥3 transaminases elevation occurring during treat-
ment, withhold therapy, resume after return to baseline
daratumumab no dose adjustment no dose adjustment for mild hepatic impairment, no data 
in patients with moderate to severe hepatic impairment
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In the ENDEAVOR study, carfilzomib-dexamethasone 
shows a doubling of PFS compared to bortezomib- 
dexamethasone (18.7 months versus 9.4 months), 
regardless of the number of prior therapy lines or prior 
exposure to bortezomib or lenalidomide.60,61 Of note, 
the dose of carfilzomib used is twice the FDA label 
dose (56mg/m2).
Combined with lenalidomide and dexamethasone in 
the ASPIRE trial, carfilzomib was associated with an 
unprecedented PFS of 26 months compared to seven- 
teen months in the lenalidomide-dexamethasone (Rd) 
control group, with a clinically relevant 31% decrease 
in the risk of disease progression or death. The ORR 
was also higher with a longer median DOR. The benefit 
was observed across all subgroups including patients 
previously exposed to bortezomib or lenalidomide and 
those with a high cytogenetic risk. Common adverse 
events were reported at a higher rate, including 
diarrhoea, cough, fever and hypertension, leading to 
treatment discontinuation in 15% of patients, but 
superior health-related quality of life was reported 
in the carfilzomib group, according to QLQ-C30.62 
The carfilzomib-lenalidomide-dexamethasone combina-
tion (KRd) is reimbursed in second line therapy since 
November 1st, 2016. Common carfilzomib-containing 
combinations are listed in Tables 4 & 5.
Ixazomib is a new generation PI, the first orally bio-
available, reversibly binding PI. With a molecular back-
bone similar to that of bortezomib, it exhibits however 
distinct pharmacological properties, with superior tissue 
penetration and higher biological activity.63 In the TOUR-
MALINE-MM2 trial, ixazomib combined with lenalido-
mide and dexamethasone improves PFS in comparison 
to Rd.64 It has the advantage of a once-weekly oral admi-
nistration, little neurotoxicity, but induces more gastroin-
testinal adverse effects compared to bortezomib (Table 5).
CYTOTOXIC AGENTS
Bendamustine is a bi-functional alkylating agent approved 
for the treatment of de novo MM that cannot be treated 
with thalidomide or bortezomib because of pre-existing 
polyneuropathy. Promising results and good tolerability 
have been reported in association with thalidomide, 
lenalidomide or bortezomib in RRMM (Table 4).65-68
Cyclophosphamide or melphalan can also be combined 
with bortezomib, lenalidomide or pomalidomide. 












































































Bortezomib X X X X X X X
Carfilzomib X X X X X X X X
Thalidomide X X X X X X X X
Lenalidomide X X X X X X X X X X X X
Pomalidomide X X X X X X X X
Cyclophosphamide X X X X X
Panobinostat X X X X X X




Anthracyclines have marginal single-agent activity in 
MM. Combination of pegylated liposomal doxorubicin 
(PLD) with bortezomib has been reported to be superior 
to bortezomib alone in terms of TTP (9.3 months versus 
6.5 months) in a phase III randomised trial, but long-
term follow-up failed to identify any survival advan- 
tage.54,69 PLD is however infrequently used in the treat-
ment of RRMM given the availability of other active 
agents (Table 4).
High-dose chemotherapy such as DCEP and DT-PACE 
can be given in RRMM, but are associated with short 
duration responses.70
HISTONE DEACETYLASE INHIBITORS (HDACi)
Histone deacetylases (HDACs) are enzymes that remove 
acetyl groups from proteins, and have the ability to 
modulate oncogenesis through epigenetic activity on 
both histone and non-histone proteins such as tumour 
protein p53, heat shock protein HSP 90 and BCL-6. 
In MM cells, HDACi inhibit cell growth and induce 
apoptosis.47 
Vorinostat was the first pan-HDAC inhibitor evaluated 
in clinical trials. It does not have any activity as single- 
agent. In the VANTAGE phase III trial, vorinostat com-
bined with bortezomib and dexamethasone showed a 
PFS advantage of only one month compared to bortezo-
mib-dexamethasone, at the cost of a low safety profile.71
Panobinostat, is an oral pan-HDAC inhibitor approved 
in 2015 for the treatment of relapsed and refractory 
MM, in patients who received at least two prior regimens 
including bortezomib and an IMiD. It blocks the aggre-
some pathway, an alternative route for cells to bypass 
the lethal effects of proteasome inhibition. The rationale 
to combine bortezomib and panobinostat is to simul- 
taneously block both the proteasome and aggresome 
pathways.72 In the PANORAMA phase III trial, panobi-
nostat combined with bortezomib and dexamethasone 
demonstrated a significant advantage in terms of PFS 
(12 months versus 8.1 months in the control arm), at 
the cost of grade 3 diarrhoea and fatigue.73 Patients who 
received prior bortezomib plus IMiD derived the greater 
benefit in terms of PFS (Tables 4 & 5).74
PRACTICE GUIDELINES
TABLE 8. Reimbursement criteria: indications in RRMM.
thalidomide no specific limitation
lenalidomide in association with dexamethasone in RRMM  patients who have already received one 
prior line of therapy
pomalidomide in association with dexamethasone in RRMM patients that have already be treated by 
2 lines of therapy including lenalidomide and bortezomib, and in whom disease has 
progressed while under therapy
bortezomib as single-agent therapy, or in association with pegylated liposomal doxorubicin or 
dexamethasone, in RRMM patients that have already received one prior line of therapy,




in association with bortezomib in RRMM patients who have already received one prior line 
of therapy, and have been treated or are ineligible to autologous stem cell transplantation
carfilzomib reimbursed in second line of therapy in association with lenalidomide and dexamethasone 
since November 1st, 2016. Reimbursement pending in other indications
elotuzumab reimbursement pending
daratumumab reimbursed in relapsed and refractory MM, who have received at least a PI and an IMiD, 
and in whom disease has progressed under the last therapy, since March 1st, 2017
panobinostat reimbursed in association with bortezomib and dexamethasone, in RRMM that have  
already received at least two lines of therapy including bortezomib and an IMiD,  




1 Before determining the treatment strategy in relapsed/refractory MM, several factors should be taken 
into consideration, such as disease- and patient-related factors, prior treatment response, and history  
of toxicities. 
2 When available, patients should always be considered for enrolment in a clinical trial. 
3 In patients achieving a high quality response, prolonged response (more than six months after stopping 
therapy) with minimal toxicity, re-administration of the agent initially proven to be effective can be  
considered. The duration of therapy is still a matter of debate, and depends on the drug regimen that  
has been previously used and the aggressiveness of the disease. In the absence of toxicity and in  
high-risk MM, regimens are preferably continued until progression. It might be reasonable, in some cases, 
to stop therapy once a stable plateau has been reached in order to limit the risk of serious toxicities.
4 In aggressive relapse, triple combinations should be used, while in selected patients with indolent relapse 
or frailty, double regimens can be considered.
5 In first relapse, 
•  Both bortezomib and lenalidomide, combined with dexamethasone, are effective. There is no specific 
preference between those drugs, the choice being based on response and tolerability to immediate 
prior therapy, co-morbidities and clinical status. 
•  Efficacy of bortezomib is increased in combination with thalidomide, lenalidomide, cyclophosphamide 
or pegylated liposomal doxorubicin. Patients should be carefully monitored for neuropathy, the dose 
and schedule is to be reduced in case of occurrence.
•  Lenalidomide can also be combined with various agents including bortezomib and cyclophosphamide, 
or new agents such as carfilzomib or elotuzumab.
•  Carfilzomib is a more active proteasome inhibitor compared to bortezomib, which has been approved 
in combination with either lenalidomide-dexamethasone or dexamethasone alone, for the treatment 
of RRMM patients who have received at least one prior line of therapy, by the European Medicines 
Agency (EMA). More data are needed before concluding that carfilzomib is preferred than bortezomib 
at relapse, especially since bortezomib is more convenient and less expensive. Carfilzomib is  
associated with a low incidence of PN. Physicians should be aware of serious cardiac side effects 
associated with carfilzomib in a small proportion of patients (5%), especially in the elderly (>75 y).  
The KRD regimen is reimbursed in Belgium in first relapse since November 1st, 2016.
Among other medications also approved by the EMA:
•  Panobinostat is the first HDACi approved for the treatment of RRMM after one prior line of therapy,  
in combination with bortezomib and dexamethasone.
•  Elotuzumab is a MoAb indicated, in combination with lenalidomide and dexamethasone, for the  
treatment of RRMM patients who have received at least one prior therapy.
6  In second relapse and beyond, 
•  Pomalidomide combined with dexamethasone is reimbursed in patients who have received at least 
two prior treatment regimens, including both bortezomib and lenalidomide, and have demonstrated 
disease progression on the last therapy. Efficacy can be increased in triplet combination using  
cyclophosphamide.
•  Daratumumab has been approved in monotherapy for the treatment of RRMM patients whose prior 
therapy included a proteasome inhibitor and an immunomodulatory agent and have demonstrated disease 
progression on the last therapy. Reimbursed in relapsed and refractory MM, who have received at least 
a PI and an IMiD, and in whom disease has progressed under the last therapy, since March 1st, 2017.
7 Younger fit patients, especially those with aggressive relapse, should preferably be treated with  
carfilzomib- or pomalidomide-based regimens. Frail patients or patients with an indolent relapse should 




Elotuzumab is a human monoclonal antibody (Moab) 
that targets the cell surface glycoprotein CS1 (SLAMF7, 
signalling lymphocytic activation molecule F7) highly 
expressed on MM cells but with limited expression 
on normal cells. Binding to this receptor mediates anti-
body-dependent cell-mediated cytotoxicity (ADCC) in 
MM cells. 
Elotuzumab (Elo) has little activity as single-agent, but 
has demonstrated synergistic activity when combined 
with lenalidomide and dexamethasone (Rd). In the 
ELOQUENT phase III trial, Elo-Rd demonstrated a 
better PFS (19.4 months versus 14.9 months) compared 
to Rd, with more than 80% ORR without significant 
toxicity.75 Response rates were comparable in RRMM 
patients with poor and standard cytogenetics. Adverse 
reactions are primarily infusion-related that can be 
readily managed using premedication with cortico- 
steroids and H1/H2 blockers. Elotuzumab has also 
been combined with bortezomib or thalidomide with 
clinical benefit (Tables 4 & 5).76,77
Daratumumab is a humanised IgG MoAb that targets 
CD38 on MM cells with a broad-spectrum mechanism 
of cell killing, including ADCC, complement-dependent 
cytotoxicity (CDC) and phagocytosis. Unlike elotuzu-
mab, daratumumab does have single-agent activity.
In a phase I-II trial, daratumumab monotherapy showed 
encouraging efficacy in patients of whom 75% were 
refractory to bortezomib and lenalidomide, with an 
ORR of 36% at the dose of 16 mg/kg, and a median 
PFS of 5.6 months. In addition, 65% of patients who 
achieved at least a response remained free of progression 
at twelve months.78 These results were confirmed in a 
pooled population of double refractory patients, heavily 
pretreated (median of five prior lines of therapy), with 
rapid (median time to response, one month), deep (14% 
with ≥ very good partial response (VGPR)), and durable 
responses (median DOR, 7.6 months), and a median 
OS of 20.1 months. Of importance, a clinical benefit was 
also noted in patients achieving MR or stable disease, 
with an OS benefit of more than twelve months.79 Similar 
to other MoAb therapies, adverse reactions include 
hypersensitivity infusion reactions that can be mitigated 
by using adequate premedication. Clinical trials have 
been initiated using various combinations of dara- 
tumumab with other drugs. Daratumumab given in 
association with bortezomib and dexamethasone (DVD) 
or lenalidomide and dexamethasone (DRD) seems 
particularly efficient with significantly higher rates of 
ORR and longer PFS (Tables 4 & 5).80,81
OTHER EMERGING OPTIONS 
Other promising agents include marizomib (a new PI), 
oprozomib (an oral PI related to carfilzomib), filanesib 
(a kinesin spindle protein inhibitor), dinaciclib (a cyclin- 
dependent kinase inhibitor), venetoclax (ABT-199, a 
selective BCL-2 inhibitor), LGH-447 (a pan-PIM kinase 
inhibitor), SAR650984 (an anti-CD38 MoAb), and roci-
linostat (a selective HDAC6 inhibitor). Each of these 
agents has single-agent activity in relapsed MM.
PRACTICE GUIDELINES
8 Patients in relapse that are double refractory to bortezomib and lenalidomide should be proposed a regimen 
containing pomalidomide or carfilzomib, or be considered for a daratumumab-based combination, or the 
addition of panobinostat to a PI, or any regimen containing PLD. Access to carfilzomib, daratumumab, 
panobinostat is currently restricted.
9 Patients with aggressive relapse with secondary plasma cell leukaemia or EM disease require drug  
combinations such as VDT-PACE.
10 Salvage autologous stem cell transplantation in transplant eligible patients with relapse or progression 
may be considered in those that already responded to a previous HDT and achieved at least a two year 
PFS with no maintenance therapy. It is also indicated in transplant eligible patients that did not receive 
HDT and ASCT as upfront therapy.
11 Allogeneic stem cell transplantation remains a curative but experimental option to be performed in the 
context of clinical trials, particularly in high-risk disease and in the presence of an unfavourable karyotype 
during first-line treatment or at first therapy-sensitive relapse. 
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HIGH DOSE THERAPY WITH 
AUTOLOGOUS AND ALLOGENEIC STEM 
CELL TRANSPLANTATION
Autologous stem cell transplantation remains an option 
in transplant eligible patients with relapse or progression, 
particularly if they did not receive HDT and ASCT at 
diagnosis. After a previous autograft, several reports on 
salvage ASCT suggest a clinical benefit with an approxi-
mate ORR of 65%, and PFS and OS approaching twelve 
and 32 months, respectively. These studies are limited 
by being mainly retrospective, having patient selection 
bias and not using new drugs induction therapies.82 In 
a phase III trial, salvage ASCT compared to conventional 
chemotherapy alone appears to improve PFS but not 
OS. Patients with adverse cytogenetic risk profile did 
not benefit from the procedure.14 Patients that already 
responded to a previous HDT and achieved at least a 
two year PFS appear to benefit the most, even in more 
advanced age.14,16,83,84 At relapse, ASCT remains an 
option in transplantation-eligible patients that did not 
receive HDT and ASCT at diagnosis. Post-ASCT strate-
gies are under investigation.
Allogeneic stem cell transplantation (alloSCT) could be 
a therapeutic option for some MM patients, but its role 
and timing is still a subject of debate. Myeloablative 
conditioning results in long-term PFS but is challenged 
by its high treatment-related morbidity and mortality. 
Reduced intensity allogeneic transplantation has been 
developed in order to still allow a graft-versus-myeloma 
effect while reducing conditioning-related toxicities. 
Young high-risk patients with an early relapse after 
first-line treatment (i.e. cytogenetics, EM disease, plasma 
cell leukaemia) who achieved a good quality response 
with salvage therapy, could be considered for alloSCT, 
preferably in the context of clinical trials, using borte-
zomib or newer agents for graft modulation post-trans-
plant.16,82 Physicians should balance the risk of graft-
versus-host disease, increased susceptibility to infections 
and the gain in disease control. 
HIGH RISK SITUATIONS
RENAL FAILURE
Renal dysfunction is common in RRMM, particularly in 
the elderly, either in relation to disease progression or co- 
morbidities (diabetes, hypertension, use of nephrotoxic 
drugs), and may have an impact on treatment decisions. 
Several drugs do not require dose adjustments: PIs, 
thalidomide, cyclophosphamide, PLD and pomalido-
mide. Lenalidomide does require dose adaptations. 
Recommended dose adjustments are listed in Table 6.
HIGH-RISK CYTOGENETICS
In RRMM patients with high-risk cytogenetics such as 
t(4;14) and del(17p), decision making on salvage therapy 
is difficult because of the absence of prospective trials. 
Current data on newer agents indicate that they may 
partly overcome the deleterious impact of high-risk 
abnormalities in this setting. Lenalidomide-dexame-
thasone is a suboptimal regimen unable to overcome 
the negative impact of del(17p), and probably t(4;14)
(conflicting results).11,85 In contrast, pomalidomide is the 
first drug to have shown an increase activity in del(17p), 
but not in t(4;14) MM patients.42,56 Deeper responses 
have been observed in heavily pretreated high-risk MM 




Patients with RRMM are more at risk of frequent infec-
tions, bone disease or anaemia.
Infections with encapsulated germs should be managed 
proactively, and patients should be vaccinated against 
influenza, haemophilus influenza and pneumococcus. 
Intravenous bisphosphonates should be started or 
restarted at relapse, in combination with calcium and 
vitamin D supplementation. Local radiation therapy 
(20-40 Gy) may be required for local bone lesions in 
case of pain or imminent fracture. Anaemia should be 
treated with EPO (erythropoietin 40.000 UI per week, 
or darbepoetin 500 μg per three weeks) or transfusion.86 
Prevention of polyneuropathy and thrombosis should 
follow the published guidelines.87
Common side effects observed with current myeloma 
drugs are reported in Table 7. 
Carfilzomib has been associated with cardiac adverse 
events (congestive heart failure and cardiac arrest) that 
have led to treatment discontinuation in a small propor-
tion of patients; electrocardiogram, pulmonary function 
tests, echocardiography should be recommended prior 
to carfilzomib treatment.88
It is important to draw attention to the fact that dara- 
tumumab interferes with routine blood-compatibility 
testing. Daratumumab in patient plasma directly binds 
to CD38 on reagent red cells used in the blood bank, 
causing a false positive antibody screen. Neutralising 
procedures have been developed.
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